Clinical trials
Real World Study clinical trials
Below are recruiting real world study clinical trials, each written for real people, not researchers. We’re tracking 355 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06470347RecruitingPhase 1/Phase 2
Testing Pyrrolitinib After Trastuzumab for HER2+ Breast Cancer
This study tests if taking pyrrolitinib (a targeted medicine) can further reduce the risk of breast cancer returning in patients with HER2-positive early breast cancer who have already received trastuzumab after surgery.
Zunyi, GuizhouAges 18–75 - NCT06361589Recruiting
Lorlatinib for advanced ALK-positive lung cancer
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
Chengdu, SichuanAges 18 years+ - NCT06726720Recruiting
Real-world study of approved lung cancer drugs
This study looks at how well approved AstraZeneca drugs work for non-small cell lung cancer in everyday medical practice. It does not test new treatments, but gathers information to help doctors and patients make better decisions.
Aix-en-ProvenceAges 18 years+ - NCT07117227Recruiting
Study to test a kidney cancer prediction model
This study is checking how well a model can predict the outcomes for people with kidney cancer who have had surgery. It looks at your medical records after surgery to help doctors better understand your recovery and future risks.
Beijing, Beijing MunicipalityAges 18–80 - NCT07165717Recruiting
Real-world study of breathing emergencies in ICU patients
This study looks at why some patients develop severe breathing problems in the ICU. It focuses on people who already have conditions like severe infections, injuries, or heavy bleeding that can stress the lungs.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07279402Recruiting
Real-world study of atezolizumab for advanced lung cancer
This trial looks at how well atezolizumab works for people with stage IV non-small cell lung cancer that has a high level of PD-L1 (a protein that helps cancer hide from the immune system). It's for people getting atezolizumab as their first treatment.
AdanaAges 18 years+ - NCT07374614Recruiting
Study of iruplinalkib after lorlatinib for ALK-positive lung cancer
This trial is for people with advanced lung cancer whose tumors have an ALK gene change and who have already taken a medicine called lorlatinib. It tests a new drug, iruplinalkib, to see how well it works for those who stopped responding to or couldn't tolerate lorlatinib.
Shenzhen, GuangdongAges 18 years+ - NCT07566559Recruiting
Rectal Cancer Treatment Before Surgery Study
This study follows real-world treatment of locally advanced rectal cancer (cancer that has grown into nearby tissues but hasn't spread to distant organs) in patients who receive chemotherapy and/or radiation before surgery. Researchers track how different treatment approaches work to help improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05570149Recruiting
Study of eptinezumab in people with frequent migraine
This real-world study looks at how well eptinezumab (an antibody medicine for migraine prevention) works for people with frequent episodic or chronic migraine as they get usual care. You may be asked to share health information and treatment details to see what helps most in everyday life.
Roma, RMAges 18–75 - NCT05391815Recruiting
Observational study of endovascular treatment for blocked leg arteries
This is a real-world observational study that follows people who get minimally invasive procedures to treat blocked arteries in the lower abdomen and pelvis. It aims to understand how well these treatments work in the middle and long term.
ShanghaiAges 18–80 - NCT07743996Recruiting
Emotional and social experiences with fibrosis medications
This study looks at how people with pulmonary fibrosis feel emotionally and socially while taking antifibrotic medications like nintedanib or pirfenidone. It aims to understand the real-world impact of these treatments on daily life.
TokyoAges 40 years+ - NCT06195228RecruitingPhase 4
Real-world study of genetic types in advanced thyroid cancer
This study looks at how different genetic types of advanced thyroid cancer respond to treatment in real-world settings. It may help doctors choose the best therapy for you based on your tumor’s genetic makeup.
Fuzhou, FujianAges Any age - NCT05144035RecruitingPhase 4
Early growth-hormone treatment for small baby’s brain development
This study tests whether starting a growth hormone treatment early helps a baby’s thinking and learning development. It is for babies who are small for their gestational age and show delays on a developmental screening test.
Wuhan, WuhanAges 6 months–2 years - NCT07640997Recruiting
Real-world study of aflibercept for age-related macular degeneration
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
Beijing, Beijing MunicipalityAges 50 years+ - NCT07198217RecruitingPhase 2
Chemo, radiation, and immunotherapy for lung cancer
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
Zibo, ShandongAges 18–75 - NCT07559695Recruiting
Menin inhibitor maintenance therapy after stem cell transplant
This study tracks how well a newer drug class (menin inhibitors) works to prevent acute leukemia from coming back after a stem cell transplant. You would be observed for safety and effectiveness if you're already taking one of these drugs.
Suzhou, JiangsuAges 15 years+ - NCT06966141Recruiting
Real-World Study of Sacituzumab Govitecan for Breast Cancer
This study looks at how well the drug Sacituzumab Govitecan works in real-life settings for people with certain types of advanced breast cancer that have not responded to prior treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05991206Recruiting
Atezolizumab with chemo before surgery for lung cancer
This study tests a combination of the immunotherapy drug atezolizumab with standard chemotherapy given before surgery for people with stage II to IIIB non-small cell lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improve outcomes.
Changsha, HunanAges 18 years+ - NCT07421895Recruiting
Study on retained tissue after pregnancy
This study follows patients with retained products of conception (tissue left in the uterus after a pregnancy) to see how they are managed in real-world medical practice. You may join if an ultrasound shows a tissue area of at least half a centimeter.
Changsha, HunanAges 18–45 - NCT06779435Recruiting
Tucidinostat-based treatment for untreated DLBCL
This trial tests a treatment plan that includes the drug tucidinostat for people who have not yet been treated for a type of lymphoma called DLBCL. It focuses on patients whose cancer cells have certain features (double expression of MYC and BCL2, or certain gene changes) that might affect how well standard treatments work.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07375355Recruiting
A study of Scemblix for newly diagnosed chronic myeloid leukemia in China
This study looks at how well the medicine Scemblix (asciminib) works for people in China who have just been diagnosed with a certain type of leukemia (chronic myeloid leukemia in chronic phase). It aims to see if starting this treatment soon after diagnosis is effective and safe.
Wuhan, HubeiAges 18–99 - NCT06893328Recruiting
Real-world study of primary membranous nephropathy
This study looks at how well a treatment works for people with primary membranous nephropathy (PMN), a kidney condition. It is meant for patients who still have high protein in their urine despite taking standard blood pressure medicines.
Guangzhou, GuangdongAges 18 years+ - NCT05703191Recruiting
Tests an inhaled nitric oxide system for newborn lung pressure
This study looks at whether an inhaled nitric oxide generator and delivery system can help newborns with high lung blood pressure (pulmonary hypertension). It may help improve oxygen levels during breathing support, but it requires specific medical eligibility and informed consent.
Guangzhou, GuangzhouAges Any age - NCT07269236Enrolling by invitation
Study of AI using medical images and records
This trial uses artificial intelligence to analyze your pathology slides, radiology images, and medical records together. It aims to see how well AI can help with diagnosis or treatment planning, and you may qualify if your medical data is available and of good quality.
Guangzhou, GuangdongAges 18 years+
Hear when a new Real World Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for real world study?
- Yes. Clin2 currently lists 355 recruiting real world study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a real world study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a real world study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.